Study guide
17.2 Cannabis Use Disorder: Epidemiology, Assessment & Treatment Evidence
Certified Addictions Registered Nurse - Advanced Practice CARN-AP
Track your progress as you read
Finished sections get a check mark.
1 Introduction: The CARN-AP Examination & Foundations of Advanced Addictions Practice
About the CARN-AP Examination: Blueprint, Scoring & Eligibility The Neurobiology of Addiction: Binge, Withdrawal & Preoccupation Screening, SBIRT & the ASAM Criteria Levels of Care
2 Chapter 1: Opioid Use Disorder: Assessment, Overdose Response & Methadone Maintenance
1.1 OUD Assessment, DSM-5-TR Diagnostic Criteria, and Clinical Opiate Withdrawal Scale (COWS) 1.2 Methadone Pharmacology, OTP Federal Regulations, QTc Prolongation & CYP450 Interactions 1.3 Opioid Overdose Assessment, Harm Reduction, Naloxone Formulations & Nalmefene
3 Chapter 2: Buprenorphine Protocols, Long-Acting Injectables & Naltrexone
2.1 Buprenorphine Pharmacology, Standard Office/Home Induction & Precipitated Withdrawal Management 2.2 Low-Dose Micro-Induction (Bernese Method) & Fentanyl Transition Strategies 2.3 Long-Acting Injectable Buprenorphine (Sublocade, Brixadi) & Extended-Release Naltrexone (Vivitrol)
4 Chapter 3: Alcohol Use Disorder: Neurobiology, Assessment & Acute Withdrawal
3.1 AUD Neurobiology, Epidemiology, Screening Instruments (AUDIT, AUDIT-C, CAGE) & Laboratory Biomarkers 3.2 Alcohol Withdrawal Syndrome, CIWA-Ar Protocol, Symptom-Triggered Benzodiazepine Regimens & Delirium Tremens 3.3 Wernicke-Korsakoff Syndrome, High-Dose Parenteral Thiamine Protocols & Acute Medical Complications
5 Chapter 4: Medications for Alcohol Use Disorder (MAUD)
4.1 Oral and Injectable Naltrexone for AUD: Mechanism, Prescribing Protocols & Clinical Efficacy 4.2 Acamprosate Calcium: NMDA Modulation, Renal Dosing Parameters & Abstinence Maintenance 4.3 Disulfiram and Second-Line / Off-Label MAUDs: Topiramate, Gabapentin & Baclofen
6 Chapter 5: Stimulant, Sedative-Hypnotic & Synthetic Substance Use Disorders
5.1 Stimulant Use Disorder (Cocaine & Methamphetamine): Neurotoxicity, Medical Emergencies & Evidence-Based Interventions 5.2 Sedative, Hypnotic, and Anxiolytic Disorders: Dependence Physiology, Risks & Outpatient Tapering Protocols 5.3 Emerging Synthetic Drugs: Fentanyl Analogues, Synthetic Cathinones, Cannabinoids & Xylazine-Associated Necrotic Wounds
7 Chapter 6: Tobacco and Cannabis Use Disorders: Evidence-Based Pharmacotherapy & Interventions
6.1 Tobacco Use Disorder & Nicotine Dependence: Dual NRT, Varenicline & Bupropion Prescribing Protocols 6.2 Cannabis Use Disorder, Synthetic Cannabinoids & Cannabinoid Hyperemesis Syndrome 6.3 Behavioral Therapies in Substance Use: Motivational Interviewing, CBT & Contingency Management
8 Chapter 7: Psychiatric Differential Diagnosis & Medical Mimics in Addictions
7.1 Diagnostic Formulation: Primary vs. Substance-Induced Psychiatric Disorders & The 30-Day Rule 7.2 Endocrine, Neurological, and Metabolic Mimics of Substance Intoxication and Withdrawal 7.3 Decisional Capacity, Competency, and Involuntary Commitment in Acute Addiction Practice
9 Chapter 8: Co-Occurring Psychiatric Disorders: Integrated Treatment Planning
8.1 Integrated Dual Diagnosis Treatment (IDDT) Framework & High-Prevalence Mood / Anxiety Co-Occurring Disorders 8.2 Complex Severe Mental Illness: Psychotic Disorders, Bipolar Disorder & Borderline Personality in Addictions 8.3 Trauma-Informed Care, PTSD, and Addictions: Evidence-Based Integrated Psychotherapy
10 Chapter 9: Pain Management in Substance Use Disorders & CDC 2022 Guidelines
9.1 CDC 2022 Clinical Practice Guideline for Prescribing Opioids for Chronic Pain: Individualized Assessment vs. Hard Caps 9.2 Multimodal Non-Opioid Pharmacotherapy, Interventional Modalities & Non-Pharmacological Strategies 9.3 Acute Pain Management in Patients on Maintenance MOUD (Methadone, Buprenorphine, Naltrexone)
11 Chapter 10: Perinatal Substance Use, Neonatal Abstinence & Infectious Complications
10.1 Perinatal Substance Use Disorder: ACOG/ASAM Guidelines, MOTHER Trial & Maintenance MOUD 10.2 Neonatal Abstinence Syndrome (NAS/NOWS): Finnegan Scoring vs. Eat, Sleep, Console (ESC) & Breastfeeding 10.3 Infectious Complications in People Who Inject Drugs: Viral Hepatitis, HIV, Endocarditis & PrEP/PEP
12 Chapter 11: Federal Regulations, Confidentiality & Controlled Substance Prescribing
11.1 Controlled Substances Act, DEA Registration, Schedule Classifications & MAT Act of 2023 11.2 Confidentiality of Substance Use Disorder Patient Records: 42 CFR Part 2 (2024 Final Rule) & HIPAA Harmonization 11.3 Prescription Drug Monitoring Programs (PDMP) & Urine Drug Testing (UDT) Interpretation
13 Chapter 12: APRN Scope of Practice, Ethical Foundations, Harm Reduction & Research Literacy
12.1 APRN Scope of Practice, Prescriptive Authority & Collaborative Practice Regulations 12.2 Ethical Dilemmas in Addictions Nursing: Stigma, Autonomy, Justice, and Maternal/Fetal Rights 12.3 Harm Reduction Philosophy, Syringe Service Programs, Drug Checking & Overdose Prevention 12.4 Landmark Clinical Trials & Research Literacy in Addictions Medicine
14 Chapter 13: Stimulant Use Disorder in Depth — Methamphetamine, Withdrawal, Treatment & Harm Reduction
13.1 Methamphetamine Use Disorder: Pharmacology, Medical & Psychiatric Sequelae 13.2 Stimulant Withdrawal, Craving & Contingency Management 13.3 Pharmacotherapy Research for Stimulant Use Disorder 13.4 Stimulant Harm Reduction, Overamping & Patient Education
15 Chapter 14: Medical Consequences of Alcohol Use — Liver, Heart, Cancer & Nutrition
14.1 Alcohol-Associated Liver Disease: Staging, Scoring & Management 14.2 Cardiovascular, Oncologic & Nutritional Consequences of Alcohol
16 Chapter 15: Brief Intervention, Drinking Goals & Recovery Support in Alcohol Use Disorder
15.1 Brief Intervention, Drinking Goals & Shared Decision Making in AUD 15.2 Relapse Prevention, Mutual-Help Programs & Recovery Support
17 Chapter 16: Tobacco Use Disorder in Depth — Neurobiology, Assessment & Special Populations
16.1 Nicotine Neurobiology, Epidemiology & the Tobacco Product Landscape 16.2 Tobacco Assessment & Behavioral Treatment: 5 A's, Quitlines & Incentives 16.3 Tobacco Treatment in Special Populations & Co-Occurring Disorders
18 Chapter 17: Cannabis Use Disorder in Depth — Products, Treatment & Policy
17.1 Cannabinoid Pharmacology, Potency & the Modern Product Landscape 17.2 Cannabis Use Disorder: Epidemiology, Assessment & Treatment Evidence 17.3 Medical Cannabis, Legalization Policy, Adolescent Risk & Patient Education
19 Chapter 18: Other Use Disorders — Inhalants, Hallucinogens, Process Addictions & Prescription/OTC Misuse
18.1 Inhalant Use Disorder: Volatile Solvents, Nitrous Oxide & Alkyl Nitrites 18.2 Hallucinogens & Dissociatives: Classic Psychedelics, PCP, Ketamine & HPPD 18.3 Process (Behavioral) Addictions: Gambling Disorder, Gaming & Compulsive Behaviors 18.4 Prescription & Over-the-Counter Substance Misuse: Opioids, Stimulants, Kratom & DXM
20 Chapter 19: Educating Patients, Families & the Public (CARN-AP Activity Area III)
19.1 Designing Health Teaching: Literacy, Readiness, Culture & Teach-Back 19.2 Medication Education, Informed Consent & Informed Refusal 19.3 Family & Support-System Education: CRAFT, Al-Anon & Overdose Prevention Teaching 19.4 Public, Professional & Anticipatory Guidance: Prevention and Advocacy Teaching
21 Chapter 20: Consultation, Collaboration & Care Coordination (CARN-AP Activity Area IV)
20.1 The APRN Consultation Process & Communicating Recommendations 20.2 Interprofessional Collaboration, Care Coordination & Transitions of Care 20.3 Community Resources, Systems Navigation & Collaborative Documentation
22 Chapter 21: Quality Improvement, Evidence & Leadership in Addictions Nursing (CARN-AP Activity Area V)
21.1 Outcome Measurement & Continuous Quality Improvement in Addictions Care 21.2 Policy Advocacy, Leadership & the Determinants of Addiction
17.2 Cannabis Use Disorder: Epidemiology, Assessment & Treatment Evidence
Key Takeaways Explain This Topic AI
Roughly 1 in 10 people who ever use cannabis develop cannabis use disorder, rising to about 1 in 6 among those who start in adolescence and higher still with daily use.
The Cannabis Use Disorder Identification Test Revised (CUDIT-R) is an 8-item screen with a commonly used cutoff of 8 or more for hazardous use and 12 or more suggesting a probable disorder.
No medication is FDA-approved for cannabis use disorder; N-acetylcysteine 1,200 mg twice daily has the strongest signal in adolescents and gabapentin has limited adult data.
Combined motivational enhancement therapy, cognitive behavioral therapy and contingency management delivered over about 9 to 12 sessions is the best-supported psychosocial package.
Cannabis withdrawal peaks between days 2 and 6, resolves over 1 to 2 weeks, and sleep disturbance with vivid dreams can persist for months and commonly drives relapse.
Last updated: September 2026
17.2 Cannabis Use Disorder: Epidemiology, Assessment & Treatment Evidence
Quick Answer: About 1 in 10 people who ever use cannabis develop cannabis use disorder; about 1 in 6 among those who begin in adolescence; substantially higher among daily users. Screen with the CUDIT-R (8 items; 8 or more = hazardous use, 12 or more = probable disorder). No FDA-approved medication exists. The best-supported treatment is a combined package of motivational enhancement therapy, cognitive behavioral therapy and contingency management across roughly 9 to 12 sessions . N-acetylcysteine 1,200 mg twice daily has the strongest pharmacologic signal, primarily in adolescents.
1. Epidemiology That Frames the Conversation
- Population Approximate risk of developing cannabis use disorder
- Anyone who ever uses About 10%
- Onset in adolescence About 17%
- Daily or near-daily users Roughly a third or more
Other risk multipliers: high-potency product use, concentrate/dabbing route, co-occurring psychiatric illness, family history, and early age of first use. Cannabis is also the most commonly reported substance among adolescents entering treatment.
Framing that avoids a fight: "Most people who use cannabis never develop a problem. The people who do tend to have started young, use every day, or use high-potency products. Where do you fall on those three?"
2. Screening and Diagnosis
CUDIT-R: 8 items covering frequency, hours spent stoned, inability to stop, failure to meet expectations, memory or concentration problems, use before driving or operating machinery, and whether anyone has expressed concern. 8 or more indicates hazardous use; 12 or more suggests a probable cannabis use disorder.
CAST (Cannabis Abuse Screening Test): 6 items, widely used in adolescents and in Europe.
DSM-5-TR: the standard 11 criteria with a 2 or more in 12 months threshold and severity by count (mild 2 to 3, moderate 4 to 5, severe 6 or more).
Assessment content that changes the plan: grams per day and product type; route (dabbing versus flower versus edible); time of first use each day; use before driving; whether the patient uses to sleep; and whether cannabis is being used to manage a treated or untreated psychiatric symptom.
3. Withdrawal
Cannabis withdrawal is a recognized DSM-5-TR diagnosis requiring 3 or more of seven features within about a week of cessation after heavy prolonged use: irritability/anger/aggression; nervousness or anxiety; sleep difficulty including vivid unpleasant dreams; decreased appetite or weight loss; restlessness; depressed mood; and at least one physical symptom such as abdominal pain, tremor, sweating, fever, chills or headache.
- Feature Timing
- Onset 24 to 72 hours
- Peak Days 2 to 6
- Resolution of most symptoms 1 to 2 weeks
- Sleep disturbance and vivid dreams Can persist weeks to months
The clinically decisive point: withdrawal-related insomnia is the most common reason for relapse. Address sleep aggressively and early with sleep hygiene, stimulus control, cognitive behavioral therapy for insomnia where available, and short-term non-benzodiazepine options. Avoid benzodiazepines and Z-drugs given the co-use risk profile.
4. Psychosocial Treatment
Approach Evidence Notes
MET + CBT, 9 to 12 sessions The most consistently supported adult package Brief 2-session MET produces smaller but real effects
Contingency management added to MET/CBT Improves abstinence rates beyond MET/CBT alone Same design rules as for stimulants: frequent, immediate, escalating
Multidimensional Family Therapy / Family-based therapies First line for adolescents Engages the family system rather than the adolescent alone
Adolescent Community Reinforcement Approach (A-CRA) Well-supported for youth Builds non-drug reinforcers
Brief interventions Modest effects in non-treatment-seeking adults Not sufficient for moderate or severe disorder
5. Pharmacotherapy: What Is and Is Not Supported
Agent Evidence Status
N-acetylcysteine 1,200 mg twice daily Positive in an adolescent randomized trial; a larger adult trial did not replicate Reasonable, low-risk adjunct, strongest case in adolescents
Gabapentin 1,200 mg/day One small randomized trial showed reduced use and withdrawal Limited; misuse potential in this population
Nabiximols and dronabinol (agonist substitution) Reduce withdrawal severity and improve retention; abstinence effects less consistent Nabiximols not available in the United States
- Cannabidiol Early trial data on reduced THC use Investigational
- Bupropion, SSRIs, atomoxetine, buspirone Negative or inconsistent Not recommended for the disorder itself
Quetiapine Sedating; frequently prescribed off-label for sleep Not an evidence-based treatment; weight and metabolic burden
Practical stance for the exam: the correct answer for cannabis use disorder is almost always a structured psychosocial package , with medication used to target specific symptoms such as insomnia rather than the disorder as a whole.